Press release
Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
—Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2 WILLOW
About this update from Insmed Incorporated
[{"type":"text","content":"—Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2 WILLOW Subgroup Analysis—\n—Real-World Cohort Study Shows Fewer Hospitalizations Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Who Received Early Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease vs. Patients in the Late-Diagnosis Group—\n—Analysis of WILLOW Data Demonstrates Reduction in Azurocidin-1 (AZU1) Sputum Levels with Brensocatib Treatment—\nBRIDGEWATER, N.J., May 22, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from eight presentations across three of its pillars—ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP)—at the American Thoracic Society (ATS) 2023 International Conference in Washington, D.C.\n\"We were pleased to share Insmed's breadth of new data with experts at this year's conference, including treatment-specific data and disease state findings that can help advance the care of patients with rare and serious diseases,\" said Martina Flammer, M.D., M.B.A, Chief Medical Officer of Insmed. \"Data were presented on how early diagnosis of NTM lung disease in patients with COPD may be associated with a reduction in healthcare resource utilization, particularly all-cause and respiratory-related hospitalizations. In addition, we were excited to share the latest subgroup analyses from WILLOW, which showed a reduction of exacerbations in patients with NCFBE, regardless of baseline disease severity.\"\nSummaries of these presentations follow:\nPoster: \"Outcomes of Patients With Bronchiectasis by Disease Severity: Subgroup Analysis From the Brensocatib WILLOW Study\"This subgroup analysis of the phase 2 WILLOW study (a randomized, double-blind, placebo-controlled trial of brensocatib in adults with NCFBE) compared patient characteristics and outcomes, as determined by the Bronchiectasis Severity Index (BSI), in mild (≤4), moderate (5–8), and severe (≥9) bronchiectasis subgroups.\nAt baseline, mean (standard deviation [SD]) BSI score in all patients was 8.3 (4.4).Compared with placebo, brensocatib 10 mg and 25 mg (pooled data) reduced the...